SELLAS to Present at Biotech Showcase™
January 06 2020 - 8:15AM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the
“Company”), a late-stage clinical biopharmaceutical company focused
on the development of novel cancer immunotherapies for a broad
range of cancer indications, today announced that Angelos Stergiou,
M.D., ScD h.c., President and Chief Executive Officer of SELLAS,
will present a corporate overview at the Biotech Showcase on
Monday, January 13 at 9:30 a.m. PT (12:30 p.m. ET) in San
Francisco, CA. The presentation will highlight SELLAS’ clinical and
regulatory development progress for GPS and NPS and outline
expected milestones for 2020.
A live audio webcast of the presentation will be available under
“Events & Presentations” in the Investors section of SELLAS’
website at www.sellaslifesciences.com/investors. A replay of the
webcast will be available for up to 30 days on SELLAS’ website
following the presentation.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company
focused on novel cancer immunotherapeutics for a broad range of
cancer indications. SELLAS’ lead product candidate, galinpepimut-S
(GPS), is licensed from Memorial Sloan Kettering Cancer Center and
targets the Wilms Tumor 1 (WT1) protein, which is present in an
array of tumor types. GPS has potential as a monotherapy or in
combination to address a broad spectrum of hematologic malignancies
and solid tumor indications. SELLAS’ second product candidate,
nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with
potential for the treatment of patients with early stage breast
cancer with low to intermediate HER2 expression, otherwise known as
HER2 1+ or 2+, which includes triple negative breast cancer
patients, following standard of care.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Investor ContactsWill O’ConnorStern Investor
Relations, Inc.212-362-1200ir@sellaslife.com
Investor RelationsSELLAS Life Sciences Group,
Inc.917-438-4353info@sellaslife.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024